NAMPT and NAD+ help protect the brain after subarachnoid hemorrhage
Official title: Roles of NAMPT and NAD+ in hypoxic conditioning-induced neurovascular protection in subarachnoid hemorrhage
Funded at Washington University · NIH-11364200 · Data updated 2026-11-12
Aims to find how NAMPT and NAD+ help shield the brain from injury after a type of stroke called aneurysmal subarachnoid hemorrhage.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | July 15, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $526,594 |
| NIH project number | 5R01NS128082-04 |
| Project ID | NIH-11364200 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients who have experienced aneurysmal subarachnoid hemorrhage could benefit from future therapies developed from this work.
✕Less likely to help
The study is preclinical; directly enrolled patients are not involved in this grant.
What this research studies
This project focuses on protecting the brain after aneurysmal subarachnoid hemorrhage by exploring how NAMPT and NAD+ influence early brain injury and delayed cerebral ischemia. Researchers test a conditioning-based approach, where non-harmful stress like brief hypoxia may boost the brain’s natural defenses after injury. They have shown that post-injury hypoxic conditioning and NAMPT-related pathways can reduce brain damage in experimental models, and they will investigate how these signals work together to preserve brain blood vessels and function. The work spans molecular to system-level studies to identify protective mechanisms that could translate into therapies for patients who have had SAH.
Why it matters
Potential benefit: If successful, this work could lead to new therapies that reduce brain injury and improve outcomes after SAH.
How similar studies have gone: Previous studies show that conditioning strategies can reduce brain injury in SAH models, supporting potential success with NAMPT/NAD+-related pathways.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Zipfel, Gregory J — Washington University
- Study coordinator: Zipfel, Gregory J
Related research
Other NIH-funded projects on the same topics.
-
Cognitive screening after an aneurysmal brain bleed
Using patient questionnaires to find thinking and memory problems in people recovering from aneurysmal subarachnoid hemorrhage.
-
Blood test to predict delayed brain injury after an aneurysm bleed
This project is creating a blood test to spot which people who had a brain aneurysm bleed are likely to develop delayed brain injury in the days after the bleed.
-
3D brain blood vessel model to study subarachnoid hemorrhage and test therapies
A researcher will develop a 3D printed, biomimetic brain model to study subarachnoid hemorrhage and screen potential nanoparticle-based treatments.
-
Biomarkers to Fine-Tune Intrathecal Nicardipine for Brain Bleeding-Related Stroke
Researchers are testing biomarkers to personalize intrathecal nicardipine treatment for patients after subarachnoid hemorrhage to prevent brain damage.
-
Adropin as a shield for the brain after a brain hemorrhage
A potential treatment with adropin is being studied to protect brain cells after a subarachnoid hemorrhage and reduce stroke-like damage.
-
Manganese-based compound as a potential therapy for subarachnoid hemorrhage
A new manganese porphyrin-based drug is being explored as a possible treatment to reduce brain injury after a subarachnoid hemorrhage.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.